While there is no word on the value of the deal, Gliimpse’s co-founders are entrepreneurial pros, and “veterans of eight startups.”

They self-funded Gliimpse and had, according to an earlier company statement, “exits approximating $400M.”


“This ain't our first rodeo,” stated Hariharan.

And it isn't Apple CEO Cook's first, either. The tech giant's acquisition is a sign of the health care-data market's importance and potential.

In an early August interview with Fast Company, he noted:

“We’ve gotten into the health arena. We started looking at wellness, and that took us to pulling a string to think about research; then we pulled a string a little further, and it took us to some patient care stuff; and we pulled a string that’s taking us into some other stuff.

“It’s clear that when you look at most of the solutions, whether it’s devices, or things coming up out of Big Pharma, that first and foremost they are done to get the reimbursement. Not thinking about what helps the patient.

“And, so, if you don’t care about reimbursement – which we have the privilege of doing because we have no market share of something huge, that may even make the smartphone market look small – then you begin to think about a lot of things. But the reimbursement is the thing, that’s the mental block that people have.”

Back to HCB News

Health IT Homepage